Plain-English translation of NCT06158698 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called can help patients with inflammatory cardiomyopathy—a heart condition caused by inflammation of the heart muscle. Researchers believe the medication may reduce inflammation in the heart and improve symptoms like irregular heartbeats and heart weakness. Half of the patients will receive , and half will receive a placebo (a dummy pill with no active ingredient) for 6 months.
Some patients develop long-term heart inflammation after myocarditis (inflammation of the heart muscle), which can lead to dangerous irregular heartbeats and heart failure. Currently, there's no clear treatment that targets this inflammation, so doctors want to test whether this medication can reduce inflammation and improve outcomes for these patients.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to take either the medication or a placebo pill once daily for 6 months. You will need to visit the research center for check-ups, blood tests, heart imaging scans, and heart rhythm monitoring to see if the medication helps reduce inflammation and improve your heart function. The researchers will also check whether your genetic background affects how well the treatment works for you.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
Italy